Biotech Values

[Rocky3]

$IDIX $ENTA $GILD $ABBV $JNJ - Pretty confusing. Good news for ENTA or not? With ABBV reportly in the bidding for IDIX, what does that say about the ENTA partnership/drug/drugs? ABBV and JNJ still missing a part of a pan-treatment piece of the drug? Who might have it? Both ENTA and Medivir moving up today - any evidence that either may have the missing piece? If so, both are incredibly cheap - if not, neither may be worth much in a couple years. Other thoughts? Let's see if analysts address issues raised by MRK today.